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Abstract 
Background 
ASPirin in Reducing Events in the Elderly (ASPREE), a randomized double-blind placebo-controlled 
trial (RCT) of daily low-dose aspirin (100 mg) in older adults, showed an increase in all-cause mortality, 
primarily due to cancer.  In contrast prior RCTs, mainly involving younger individuals, demonstrated a 
delayed cancer benefit with aspirin. We now report a detailed analysis of cancer incidence and mortality. 
Methods 
19,114 Australian and U.S. community-dwelling participants aged 70+ years (U.S. minorities 65+ 
years) without cardiovascular disease, dementia or physical disability were randomized and followed for a 
median of 4.7 years. Fatal and non-fatal cancer events, a prespecified secondary endpoint, were adjudicated 
based on clinical records. 
Results 
981 cancer events occurred in the aspirin and 952 in the placebo groups. There was no statistically 
significant difference between groups for all incident cancers (HR = 1.04, 95% CI = 0.95 to 1.14), 
hematological cancer (HR = 0.98, 95% CI = 0.73 to 1.30), or all solid cancers (HR = 1.05, 95% CI = 0.95 to 
1.15), including by specific tumor type. However, aspirin was associated with an increased risk of incident 
cancer that had metastasized (HR = 1.19, 95% CI = 1.00 to 1.43) or was stage 4 at diagnosis (HR = 1.22, 95% 
CI = 1.02 to 1.45), and with higher risk of death for cancers that presented at stages 3 (HR = 2.11, 95% CI = 
1.03 to 4.33) or 4 (HR = 1.31, 95% CI = 1.04 to 1.64). 
Conclusions 
In older adults, aspirin treatment had an adverse effect on later stages of cancer evolution. These 
findings suggest that in older persons, aspirin may accelerate the progression of cancer and thus, suggest 
caution with its use in this age group.  
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The ASPirin in Reducing Events in the Elderly (ASPREE) was a randomized controlled trial (RCT) 
comparing daily low-dose aspirin (100mg) versus placebo in 19,114 Australian and U.S. adults aged 70 years 
or older (or ≥ 65 years of age among U.S. African Americans and Hispanics) who were free of known 
cardiovascular disease, dementia, or physical disability at trial entry.1,2 We recently reported that ASPREE 
participants randomized to aspirin experienced higher all-cause mortality.3 This became evident at three years 
post-randomization and was largely attributable to death from cancer.  
This finding was unexpected in the context of results from prior RCTs and meta-analyses.4–6 
Generally, these studies, conducted in a younger average age-group, reported that aspirin did not affect the 
short term risk of cancer although Rothwell et al. recently reported an increase in cancer incidence during the 
early years of follow-up amongst older trial participants.7  With more prolonged follow-up, participants 
randomized to daily aspirin had a reduced risk of incident cancer and death from cancer, particularly 
colorectal cancer.7,8  This led the United States Preventive Services Task Force (USPSTF) in 2016 to 
recommend low-dose aspirin for primary prevention of cardiovascular (CVD) events and colorectal cancer 
among U.S. adults aged 50-59 with a greater than 10% ten-year risk of a CVD event.9 However, this advice 
did not extend to adults aged 70+ where the evidence was considered insufficient.9   
The present report now provides a more detailed analysis of the effect of aspirin on cancer incidence 
and mortality occurring in the ASPREE participants with the aim of better understanding the findings and 
implications of the study. 
METHODS 
Trial Design 
Details of the ASPREE trial have been described elsewhere (Trial Registration Number: ASPREE 
ClinicalTrials.gov number NCT01038583).1,2 From March 2010 through December 2014, a total of 19,114 
participants across Australia (n=16,703) and the U.S. (n=2,411) gave written informed consent and were 
randomly assigned to receive daily 100mg of enteric coated aspirin (n=9,525) or matching placebo (n=9,589). 
A previous history of cancer was not an exclusion criterion and was present in 19% of those randomized. 
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However, all participants were required to be in good health, free of major diseases and expected to survive 
for at least five years (details of follow-up and compliance in Supplementary Methods).10  
Ascertainment of cancer outcomes 
Fatal and non-fatal cancers occurring during the randomized treatment phase were a prespecified secondary 
endpoint. Detailed clinical records, including histopathology reports, were sought from treating practitioners 
and healthcare institutions when evidence of a new or recurrent cancer was recorded, or after a participant had 
died. If available, TNM staging and histological grading were also collected. When death certificates were the 
only source of information, cases where cancer was included as the underlying cause of death were included 
within the dataset (details of blinded adjudication and definitions in Supplementary Methods, Supplementary 
Box 1 and Supplementary Figure 1). 
Analyses were conducted by ‘person’ and by ‘incident cancer’, the former analysis accounting for the 
numbers of individuals developing one or more ‘cancer events’ (either a new incident cancer which could be 
localized or distant, or a metastatic recurrence of a cancer diagnosed prior to study entry) during the period of 
the trial.  The ‘incident cancer’ analysis included each new cancer subtype diagnosis reported and confirmed 
after randomization, and included the possibility for participants to contribute two or more distinct cancer 
endpoints if the subtype differed. For example, a participant diagnosed after randomization with prostate 
cancer, who subsequently developed pancreatic cancer, would contribute two incident cancers. If a subsequent 
death was considered the result of cancer, the cancer considered most likely to have led to the death was 
determined. Amongst those who entered the trial with a history of cancer, any new cancer type was included 
amongst incident cancers while a local recurrence of the same type was not (see Supplementary Figure 2). 
Distant recurrence of a primary tumor present at baseline was included as a new metastatic cancer (details in 
Supplementary Methods).  
Statistical analysis 
Cox proportional-hazards models were used in intention-to-treat analyses to compare aspirin and placebo 
groups on time-to-event cancer outcomes during the intervention phase of the trial (on or prior to 12th June 
2017, median of 4.7 years follow up for both groups). An analysis was performed for the event of ‘first 
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diagnosis’ of cancer of any type (i.e. incident cancers) that occurred during the trial, and a separate set of 
analyses, one for each anatomical cancer type, was also conducted. These analyses were all time to first event, 
and if a participant experienced multiple anatomical cancer types then only their first occurrence contributed 
to the analysis of “cancer of any type”, while their first occurrence of each specific anatomical type 
contributed to that anatomical type’s analysis. Cause-specific hazard ratios (HR) were determined for total 
cancer, non-metastatic cancer, metastatic cancer and specific cancer types with censoring at the time of the 
competing risk of death. The proportional hazards assumption was checked for all models by using a test 
based on Schoenfeld residuals. A competing risk model was used to develop the cumulative incidence plots.  
Sub-groups that were pre-specified in the trial protocol included country of residence, age, sex, 
ethnicity, smoking status, body mass index (BMI) category, prior regular use of aspirin, baseline history of 
diabetes, hypertension, dyslipidemia, and prior cancer history.1,2,11 Effect heterogeneity between subgroups 
was assessed with omnibus tests of whether coefficients for interaction terms in Cox proportional-hazards 
models were different from zero.  All p-values are two-sided, with cut-point for statistical significance p < 
0.05, and all analyses were restricted to events that occurred on, or prior to, the end of the treatment phase.  
Compliance with ethical standards 
The ASPREE trial was conducted in accordance with the Declaration of Helsinki 1964 as revised in 2008, the 
NHMRC Guidelines on Human Experimentation, the federal patient privacy (HIPAA) law and ICH-GCP 
guidelines and the International Conference of Harmonisation Guidelines for Good Clinical Practice. 
ASPREE also follows the Code of Federal Regulations as it relates to areas of clinical research. 
RESULTS 
Participants 
Baseline characteristics of the participants are presented in Table 1 showing treatment groups well balanced in 
terms of established or putative risk factors for cancer.2 Prior aspirin use was low (11.0%) and balanced across 
groups (aspirin n=1053, placebo n=1041). At the end of the trial, the total numbers of years during which 
participants were at risk of cancer mortality were 44,007 person-years in the aspirin group and 44,382 person-
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years in the placebo group. At trial entry 3,660 (19.1%) had a prior diagnosis of cancer (excluding non-
melanoma skin cancer) while 15,375 (80.4%) were not known to have cancer prior to randomization, with the 
cancer history status unknown for 79 (0.4%) (Table 1). The compliance to study medication, expressed as a 
proportion of the time in study that an individual spent taking their randomized medication, was on average 
72.7% for the aspirin group and 74.5% for the placebo group. 
Incidence 
Table 2 indicates that 981 individuals in the aspirin group and 952 in the placebo group had a first incident 
cancer after randomization, regardless of whether they had a past cancer history at baseline.  Corresponding 
numbers of deaths adjudicated as caused by cancer are also shown. During the in-trial follow-up, 1,933 
(10.1%) were diagnosed with a new incident cancer. Amongst these, 1,270 (65.7%) presented with localized 
cancer (i.e. non-metastatic cancer), 363 (18.8%) presented with new metastatic disease (i.e. incident metastatic 
disease), 113 (5.8%) presented with metastatic disease of a cancer type already present before study entry (i.e. 
metastatic recurrence) and 187 (9.7%) with a hematological or lymphatic cancer (subgroup analyses 
Supplementary Tables 1 and 2). A total of 495 (25.6%) participants died as a result of their malignancy, of 
these, 52 died from progression of a cancer initially diagnosed prior to trial entry (Table 2; CONSORT 
Diagram, Supplementary Figure 3). 
Aspirin was not associated with risk of diagnosis of a first incident cancer event (HR =1.04, 95% CI = 
0.95 to 1.14), an incident localized cancer (HR= 0.99, 95% CI = 0·89-1.11), or an incident hematological or 
lymphatic cancer (HR = 0.98, 95% CI = 0.73 to1.30). However, the number of participants with metastatic 
cancer at diagnosis (HR= 1.19, 95% CI = 1.00 to 1.43) was increased amongst those randomized to aspirin. 
Table 3 compares the impact of aspirin and placebo on the incidence of, and mortality from, solid 
tumors (i.e. excluding hematological/lymphatic cancers) according to stage and anatomical origin and Figure 
1 shows the cumulative incidence of solid tumor cancers according to stage at diagnosis. There was no 
association of aspirin with the overall incidence of solid tumors (HR = 1.05, 95% CI = 0.95 to 1.15) nor with 
the incidence of cancers that were diagnosed at stages 1, 2 or 3. By contrast, aspirin was associated with an 
increase in the incidence of cancers presenting at stage 4 (HR = 1.22, 95% CI = 1.02 to 1.45). 
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Deaths 
An increased progression to death was observed amongst those randomized to aspirin, regardless of whether 
the initial cancer presentation had been localized or metastatic (Table 2, Figure 2). Table 3 demonstrates a 
higher death rate amongst the aspirin group presenting with stage 3 (HR = 2.11, 95% CI = 1.03 to 4.33) or 
stage 4 disease (HR =1.31, 95% CI = 1.04 to 1.64).  
Prostate, colorectal, breast, melanoma, and lung were the most common incident cancers, accounting 
for 80% of all solid tumor cancers. There was no association of aspirin with the incidence of cancer in any 
anatomic subtype.  However, the aspirin-treated group was observed to have more deaths from solid tumors 
irrespective of anatomical site, including colorectal cancer deaths (35 versus 20, HR = 1.77, 95% CI = 1.02 to 
3.06). In absolute terms, the rate of solid tumor cancers with subsequent death was increased from 4.4 cases 
per 1000 person-years of observation amongst those randomized to placebo to 5.9 cases per 1000 person-years 
amongst those receiving aspirin (HR = 1.33, 95% CI = 1.11 to 1.61).  
Subgroup analyses 
The effect of aspirin on solid tumor incidence (Figure 3A), solid tumor mortality (Figure 3B) and all incident 
cancers (Supplementary Figure 4) appeared similar across a series of prespecified and non-prespecified 
subgroups. Notably an aspirin-associated non-statistically significant trend towards increasing cancer 
mortality, but not cancer incidence, was observed with age. 
Compliance-adjusted treatment effects 
Adjusting for compliance (Supplementary Tables 3 and 4) did not diminish the intention-to-treat aspirin 
effects presented in Tables 2 and 3. 
DISCUSSION 
We previously reported that amongst older adults taking low-dose aspirin for primary prevention in 
the ASPREE RCT, there was an increased mortality rate, largely attributed to a higher death rate from cancer.3 
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More deaths were observed amongst aspirin treated participants from cancers originating from a variety of 
anatomical sites, and these deaths were not attributable to a specific ‘proximal’ cause of death such as 
bleeding.3 
In this paper we provide a more detailed assessment of the cancer incidence and mortality from cancer 
amongst the major cancer subtypes according to stage of disease at presentation, to help provide a better 
understanding of the mortality findings. Essentially while the incidence of new localized cancer was similar in 
those randomized to aspirin or placebo, the number of individuals diagnosed with malignancy at an advanced 
stage (including those with metastatic cancer at diagnosis), was higher in the aspirin group.  
Additionally, a higher death rate from cancer amongst those randomized to low-dose aspirin was 
observed for all solid tumors, regardless of whether the cancer was localised or metastatic at presentation. 
This was most evident for cancers that were stage 3 or 4 at diagnosis, and for colorectal cancer. No similar 
effect was seen with blood and lymphatic cancers. There was no evidence of effect modification on mortality 
by age, sex, or risk factors for malignancy.  The impact on mortality from colorectal cancer was at least equal 
in magnitude to that at other sites, and the findings were similar among subgroups from both Australia and the 
U.S.  
The observed increase in risk of cancers presenting at an advanced stage and the increased death rate 
amongst those diagnosed with a later stage cancer, consistently observed across multiple primary sites, 
suggest that aspirin may promote the progression of advanced malignancies in this age group. Possible 
explanations for this finding include aspirin suppressing (or ‘blunting’) anti-tumor inflammatory or immune 
responses critical to controlling later stage growth and spread.12-14 Such an effect may be particularly evident 
among an older population for which underlying anti-tumor immunity may already be compromised.15  
Differences in the biology and behaviour of tumors in older adults are also well described.  For 
example, among older adults, colorectal cancer occurs more commonly in the right-side of the colon16 and has 
a higher prevalence of specific molecular changes, including deficiencies in mismatch repair and BRAF 
mutations.17 In a previous study, we observed that regular aspirin use was associated with a lower risk of 
BRAF-wild-type colorectal cancer but not BRAF-mutated colorectal cancer.18  Additionally, age has been 
shown to impact the types of mutations found within specific genes of tumors, such as the greater incidence of 
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the G12 mutation of KRAS in those under 40 compared to the more common Q16 KRAS mutation in older 
patients,19 along with a difference in the mutated gene itself.20 Other molecular changes have also been shown 
to be more prominent in cancers of older people, such as the methylation state of certain genes.20,21  
These reports make it plausible that aspirin might also act differently, at the cellular or molecular 
level, in older individuals. Our results contrast with other data from previous RCTs, summarized in earlier 
systematic reviews by Rothwell et al. (2012)4 and the USPSTF (2016)22 and Haykal et al. (2019).23 Pooled 
analysis of trials, which included populations with a mean age ~10 years younger than in ASPREE, found that 
aspirin neither increased or decreased cancer incidence or mortality during the period of aspirin intervention, 
typically 5 years.23 The recent ASCEND primary prevention trial, conducted in somewhat younger individuals 
with diabetes mellitus, also found no evidence of increased cancer mortality after 7.4 years of follow-up.24 
However the most recently published meta-analysis by Rothwell et al. (2018) reported an increase in risk of 
cancer diagnosis with low-dose aspirin amongst individuals aged 70 years and over, when follow-up was 
limited to 3 years.7 The authors noted this effect was observed only in those with low bodyweight. Statistically 
significant effects from aspirin were not seen in cancer deaths.   
Given the multiple analyses undertaken without statistical control for multiple testing, the possibility 
that findings have arisen by chance, or from a bias in the ascertainment of relevant outcomes must also be 
considered. However, the objective end-point of all-cause mortality was statistically significantly higher 
amongst those randomized to aspirin and is less likely to be a chance finding.  The difference in cancer 
mortality explained virtually all of this difference. The process for allocating cause of death required blinded 
adjudicators to confirm all cancer diagnoses and determine the underlying reason for the trajectory to death, 
which reduced the likelihood of biased ascertainment of cancer end-points. In an older age group, where 
multimorbidity is common and clinical investigations may be limited, the illness ultimately leading to death 
frequently requires a review of clinical documentation to determine the most likely pathology. This process 
was undertaken to review all deaths occurring during ASPREE, in contrast with earlier aspirin trials. 
The results might also be explained if there was a bias in the ascertainment of the outcome, most 
obviously, if aspirin led to a systematic delay in the recognition of cancer, so that amongst those taking aspirin 
cancer was diagnosed at a more advanced stage. However, this is unlikely as we did not observe a time-
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dependent compensatory decrease in incidence of stage 1-3 cancers that would offset the observed increase in 
the incidence of stage 4 cancer.  As reported previously, the difference also did not appear to be explained by 
differences in the mode of death, as for example, if aspirin increased the likelihood of a patient with cancer 
dying prematurely from hemorrhage or infection.3   
During more prolonged follow-up of participants in earlier primary and secondary prevention trials, a 
delayed protective effect of aspirin on cancer incidence and mortality has been observed, particularly for 
colorectal cancers.8,22 In 2010, Rothwell and colleagues reported a long-term follow-up of participants from 
four large randomized trials of aspirin (75-300mg/d) which found that allocation to aspirin reduced the 20-
year risk of cancer mortality (HR 0.65, 95% CI 0.48-0.88) and the benefit increased with treatment duration.25 
In the Women’s Health Study (WHS, alternate-day 100-mg aspirin), aspirin was associated with reduced 
colorectal cancer incidence that became apparent during subsequent post-trial follow-up 10 years after 
randomization.26 these results are suggestive of a delayed benefit of aspirin and emphasize the importance of 
ongoing follow-up of the ASPREE cohort. 
Strengths of ASPREE include the use of blinded expert reviewers to categorize both tumor stage and 
causes of death, thus minimizing bias or misclassification. However, limited statistical power was available to 
examine the effect of aspirin within subgroups or on specific cancer subtypes and consideration about the 
multiplicity of statistical analyses also constrain some of our conclusions. Finally, although we did not 
observe a differential effect of aspirin on cancer mortality according to a history of prior aspirin use, our 
overall results do not specifically address whether aspirin use initiated at a younger age should be 
discontinued after age 65 to 70. 
If confirmed, the clinical implications of these findings could be important for the use of aspirin in an 
older population. If low-dose aspirin were to hasten the progression of cancers, its role as a primary 
prevention agent would be further diminished. However, the increased risk in ASPREE was small (an extra 
1.5 deaths from cancer per 1000 person years) in comparison with the risk of mortality from other causes. 
Several RCTs are currently underway to address the use of aspirin after diagnosis and treatment of cancer with 
curative intent, and these results may be of particular value in supporting or refuting these findings, provided 
they include sufficient numbers of older subjects.27-31  
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In summary, among generally healthy adults predominantly 70 years of age or older at enrolment and 
followed for a median of 4.7 years, daily low-dose aspirin was associated with an increased risk of incident 
solid cancers presenting at an advanced stage.  Mortality from both localized and advanced cancers was higher 
in those taking aspirin, suggesting a possible adverse effect of aspirin on cancer evolution in older adults. 
Cancer molecular and genetic data give reason to suggest that the potential adverse impact of aspirin 
identified in ASPREE might be specific to this age group.  The cohort continues to be followed to explore the 
possibility of a delayed reduction in cancer incidence and/or mortality that may emerge with longer term 
observation.  
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TABLE 1: Baseline characteristics of the ASPREE population by treatment group 
Characteristic 
Aspirin (n=9525) Placebo (n=9589) 
No. (%) No. (%) 
Age, y 
65-69 284 (3.0) 280 (2.9) 
70-74 5243 (55.0) 5356 (55.9) 
75-79 2533 (26.6) 2490 (26.0) 
80-84 1085 (11.4) 1111 (11.6) 
85+ 380 (4.0) 352 (3.7) 
Male sex 4152 (43.6) 4180 (43.6) 
BMI 25+, kg/m2 6981 (73.6) 7080 (74.2) 
Smoking 
Current 352 (3.7) 383 (4.0) 
Former 3909 (41.0) 3890 (40.6) 
Never 5264 (55.3) 5316 (55.4) 
Alcohol use 
Current 7309 (76.7) 7333 (76.5) 
Former 566 (5.9) 570 (5.9) 
Never 1650 (17.3) 1686 (17.6) 
Previous regular aspirin use* 1053 (11.1) 1041 (10.9) 
Personal cancer history 1827 (19.2) 1833 (19.1) 
Family cancer history† 5605 (58.3) 5554 (58.5) 
Previous cancer screening, % of asked ‡ 2934 (96.7) 2924 (96.6) 
*Previous regular aspirin use was defined according to participant-reported regular use of aspirin immediately
before entering the study.
†Family cancer history includes a history of cancer in the participant’s mother, father, siblings and children, as
reported by each participant at baseline.
‡Previous cancer screening questions asked of 3022 participants in the aspirin group and 3035 participants in
the placebo group
0 
TABLE 2: Number of individuals with incident cancer (n=1933) and deaths from cancer (n=495), by presentation of first cancer event, in the 
aspirin or placebo study arms (summarized as rates per 1000 person-years of follow-up)  
Cancer endpoint 
Cancer incidence* Cancer mortality†‡ 
No. individuals with cancer 
diagnosis (rate per 1000 
person-years) 
Aspirin vs Placebo 
No. individuals dying from 
cancer (rate per 1000 person-
years) 
Aspirin vs Placebo 
Aspirin Placebo Hazard Ratio (95% CI) Aspirin Placebo 
Hazard Ratio (95% 
CI) 
First incident cancer 981 (23.9) 952 (23.0) 1.04 (0.95 to 1.14) 283 (6.4) 212 (4.8) 1.35 (1.13 to 1.61) 
    Incident localized cancer 631 (15.2) 639 (15.3) 0.99 (0.89 to 1.11) 93 (2.1) 64 (1.4) 1.47 (1.07 to 2.02) 
    Metastatic cancer 258 (6.1) 218 (5.1) 1.19 (1.00 to 1.43) 171 (3.9) 133 (3.0) 1.30 (1.03 to 1.63) 
       Incident metastatic cancer 196 (4.6) 167 (3.9) 1.18 (0.96 to 1.46) 143 (3.2) 109 (2.5) 1.32 (1.03 to 1.70) 
Metastatic spread from 
cancer reported prior to 
randomization§ 
62 (1.5) 51 (1.2) 1.23 (0.85 to 1.77) 28 (0.6) 24 (0.5) 1.18 (0.68 to 2.03) 
    Hematological or lymphatic 
cancer 
92 (2.2) 95 (2.2) 0.98 (0.73 to 1.30) 19 (0.4) 15 (0.3) 1.28 (0.65 to 2.51) 
* Based on time from randomization to first incident cancer
† Based on time from randomization to cancer-related death in those who developed cancer
‡  Mortality definitions: Adjudicated cancer deaths only are included in this table. Note: 522 cancer-related deaths are reported in the recent
publication by the same first author (McNeil et al, NEJM 2018, “Effect of Aspirin on All-Cause Mortality in the Healthy Elderly”; reference 2),
whilst only 495 deaths are reported here.  Deaths that could not be adjudicated but were attributed to cancer using death certificate codes are not
included (n=7). Cancer deaths in participants who did not present with cancer prior to death are not included (n=20).
§ Metastatic cancer of the same type as pre-existing (prior to randomization) cancer
1 
TABLE 3: Cancer incidence and cancer mortality by stage, anatomical site and treatment arm, as rates per 1000 person-years of observation. 
Cancer stage at diagnosis or 
anatomical site 
Cancer incidence* Cancer mortality* 
Aspirin Placebo Aspirin vs Placebo Aspirin Placebo Aspirin vs Placebo 
No. cancer 
events (rate 
per 1000 
person- 
years) 
No. cancer 
events(rate 
per 1000 
person- 
years) 
Hazard Ratio (95% CI) 
No. cancer 
events (rate 
per 1000 
person- 
years) 
No. cancer 
events (rate 
per 1000 
person- 
years) 
Hazard Ratio (95% CI) 
All solid tumors† 893 (21.7) 859 (20.7) 1.05 (0.95 to 1.15) 259 (5.9) 196 (4.4) 1.33 (1.11 to 1.61) 
Stage 1 210 (5.0) 225 (5.3) 0.94 (0.78 to 1.13) 5 (0.1) 9 (0.2) 0.56 (0.19 to 1.67) 
Stage 2 219 (5.2) 236 (5.5) 0.94 (0.78 to 1.12) 16 (0.4) 9 (0.2) 1.80 (0.79 to 4.06) 
Stage 3 98 (2.3) 99 (2.3) 1.00 (0.75 to 1.32) 23 (0.5) 11 (0.2) 2.11 (1.03 to 4.33) 
Stage 4‡ 275 (6.5) 228 (5.3) 1.22 (1.02 to 1.45) 172 (3.9) 133 (3.00) 1.31 (1.04 to 1.64) 
Uncertain stage 91 (2.1) 71 (1.7) 1.29 (0.95 to 1.76) 30 (0.7) 16 (0.4) 1.89 (1.03 to 3.47) 
Anatomic site of origin 
Prostate§ 199 (11.1) 202 (11.1) 1.00 (0.82 to 1.21) 17 (0.9) 17 (0.9) 1.02 (0.52 to 2.01) 
Colorectal 139 (3.3) 137 (3.2) 1.02 (0.81 to 1.30) 35 (0.8) 20 (0.5) 1.77 (1.02 to 3.06) 
Breast‖ 127 (5.3) 124 (5.1) 1.03 (0.80 to 1.32) 15 (0.6) 7 (0.3) 2.15 (0.88 to 5.27) 
Melanoma 87 (2.0) 106 (2.5) 0.83 (0.62 to 1.10) 12 (0.3) 8 (0.2) 1.51 (0.62 to 3.69) 
Lung 86 (2.0) 84 (2.0) 1.03 (0.76 to 1.40) 55 (1.2) 51 (1.1) 1.09 (0.74 to 1.59) 
Bladder 37 (0.9) 38 (0.9) 0.98 (0.62 to 1.54) 8 (0.2) 9 (0.2) 0.90 (0.35 to 2.33) 
Brain 18 (0.4) 9 (0.2) 2.02 (0.91 to 4.49) 14 (0.3) 9 (0.2) 1.57 (0.68 to 3.62) 
Cervical‖ 2 (0.1) 1 (0.04) 2.01 (0.18 to 22.13) 0 (0.0) 0 (0.0) n/a 
Gallbladder or bile duct 11 (0.3) 12 (0.3) 0.93 (0.41 to 2.10) 8 (0.2) 8 (0.2) 1.01 (0.38 to 2.69) 
Kidney 25 (0.6) 18 (0.4) 1.40 (0.76 to 2.57) 9 (0.2) 4 (0.1) 2.28 (0.70 to 7.39) 
Liver 7 (0.2) 1 (0.02) n/a 4 (0.1) 0 (0.0) n/a 
Mesothelioma 9 (0.2) 6 (0.1) 1.52 (0.54 to 4.26) 5 (0.1) 2 (0.05) 2.53 (0.49 to 13.03) 
Oesophageal 11 (0.3) 18 (0.4) 0.62 (0.29 to 1.30) 7 (0.2) 13 (0.3) 0.54 (0.22 to 1.36) 
Ovary or endometrium‖ 40 (1.6) 37 (1.5) 1.09 (0.69 to 1.70) 15 (0.6) 13 (0.5) 1.16 (0.55 to 2.43) 
Pancreatic 37 (0.9) 29 (0.7) 1.29 (0.79 to 2.09) 29 (0.7) 21 (0.5) 1.39 (0.80 to 2.45) 
Stomach 18 (0.4) 11 (0.3) 1.65 (0.78 to 3.49) 9 (0.2) 4 (0.1) 2.27 (0.70 to 7.38) 
Thyroid 6 (0.1) 5 (0.1) 1.21 (0.37 to 3.97) 0 (0.0) 0 (0.0) n/a 
2 
Other 66 (1.5) 55 (1.3) 1.21 (0.85 to 1.73) 15 (0.3) 8 (0.2) 1.89 (0.80 to 4.46) 
Unknown 20 (0.5) 13 (0.3) 1.55 (0.77 to 3.12) 12 (0.3) 9 (0.2) 1.35 (0.57 to 3.19) 
*Cancer incidence is the first cancer event of anatomical type, noting that participants with more than one cancer type will be counted for each type. Cancer
mortality reports deaths from the same individuals included in the same row under incidence.
†Excludes hematological cancer and hematological cancer death. Stage 1 cancer incidence includes the first presentation with a cancer that was Stage 1 at
presentation. Cancer mortality is death from a cancer that was stage 1 at presentation. This format is repeated for stages 2-4 and uncertain stage.
‡Some cancer types, e.g. prostate and bladder, can have non-metastatic disease staged as Stage 4.
Cancer type is ordered with the top 5 most prevalent cancers by incident listed first, then listed alphabetically.
§ - males only; ‖ - females only;
3 
FIGURE LEGENDS 
FIGURE 1: Cumulative incidence of first incidence of solid tumor cancer, by stage and treatment group. 
FIGURE 2: Cumulative incidence of cancer–related death following a first presentation of localized or metastatic 
cancer. Panel A shows localized cancer and panel B shows metastatic cancer. Time is from randomization to the 
occurrence of death following the cancer event. 
FIGURE 3: Forest plots of solid tumor cancer incidence and mortality by sub-group. Solid tumor cancer incidence 
is shown Panel A and mortality is shown in Panel B. Subgroups are classed from baseline (enrolment) and include 
age in years, BMI (in kg/m2), prior cancer history and family cancer history. Not all participants were asked about 
cancer-related medical screening (questionnaire introduced late in recruitment, 2013).   
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